# Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.

> **NCT01756456** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 174 (actual)

## Conditions studied

- Neurotrophic Keratitis
- Keratitis
- Corneal Ulcer

## Interventions

- **DRUG:** rhNGF 10 μg/ml
- **DRUG:** rhNGF 20 μg/ml
- **OTHER:** vehicle

## Key facts

- **NCT ID:** NCT01756456
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2015-04
- **Final completion:** 2016-05
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01756456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01756456, "Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01756456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*